KPV: how a gut-cell experiment becomes a research question
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

How does a three-amino-acid peptide get inside a gut cell? That question sits at the centre of KPV research. In laboratory-grown intestinal and immune cells, researchers found that a transporter called PepT1 could carry KPV inside. Inflammatory signalling then changed. The same research reported reduced inflammation in mouse models of colitis. Human-derived cells and mice are useful steps, but neither establishes treatment benefits in patients. FDA reports a lack of human exposure information for KPV drug products. Delivery, safety and meaningful clinical outcomes remain questions to answer before making gut-healing claims.

END CARD
Evidence first. Educational only. Sources in description.

SOURCES
[1] PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
https://pubmed.ncbi.nlm.nih.gov/18061177/
Primary study; human cell lines and mouse colitis models

[2] FDA: Certain bulk drug substances that may present significant safety risks
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
US regulator; route-specific safety assessment, not a universal ban or approval list

EVIDENCE LIMITATIONS
Do not turn PepT1 transport into a claim of proven oral bioavailability or clinical gut healing.
Do not extrapolate induced mouse colitis to treatment of human Crohn disease or ulcerative colitis.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/1115627857845670/